Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT07693894
Recruiting Observational

Innovative Ovarian Cancer Biomarker Assays

NCT07693894 · tracked via the Priya Life Science Czechia tracker
Sponsor
National and Kapodistrian University of Athens
Phase
Observational
Started
2026-08-03
Last updated
2026-10-01

Condition(s) studied

Ovarian Cancer

Investigational drug(s) / intervention(s)

Investigational ovarian cancer biomarker assays

Investigational ovarian cancer biomarker assays: Collection of blood samples for investigational ovarian cancer biomarker analyses (OVA-GLY, OVA-VOC and OVA-miRNA).

Study summary

Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes.

Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care.

The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer.

The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer.

This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.

Eligibility

Sex
FEMALE
Min age
35 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: EOC patients 1. Women, trans men and non-binary people with female reproductive organs 2. Aged ≥35 years\* 3. Pathologically diagnosed, by biopsy, with EOC prior to surgical intervention or treatment 4. Presenting with adnexal mass suspicious of OC on imaging and scheduled for surgical resection or biopsy (and subsequent confirmation of EOC) 5. Able to give informed consent Healthy controls 1. Women, trans men and non-binary people with female reproductive organs 2. Aged ≥35 years 3. No cancer history 4. Able to give informed consent Exclusion Criteria: 1. Prior history and any treatment for malignancy 2. Prior removal of either ovary for any reason 3. Pregnant or lactating 4. Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Vseobecna Fakultni Nemocnice V Praze Prague Czechia Recruiting
Fakultni Nemocnice Bulovka Prague Czechia Recruiting
National Centre for Scientific Research Demokritos Athens Attica Recruiting
Dept of Clinical Therapeutics, Alexandra Hospital Athens Greece Recruiting
Lithuanian University of Health Sciences Kaunas Lithuania Not Yet Recruiting
Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. Lisbon Portugal Recruiting
Imperial College Healthcare NHS Trust Hammersmith Hospital London United Kingdom Recruiting

Other trials for the same condition

CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA) Recruiting
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Active, not recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) Recruiting
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07693894 on ClinicalTrials.gov ↗ ← All trials in Czechia